Insights on the CONTACT03 Trial Results and Implications

Analyzing response rates of cabo-santinib, understanding confidence intervals, challenges in subgroup analysis, and toxicity profile in metastatic RCC patients post-progressing on prior treatment. Discussion on lack of clinical improvement with immunotherapy and increased toxicity in the combination treatment arm.